This week, Recursion made the tough decision to lay off 20% of its workforce, a move described as painful but necessary for the company’s mission. This trend of layoffs and corporate restructuring is reflective of broader challenges in the biotech sector, including struggling stocks, limited capital, and decreased federal funding for startups.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.statnews.com/2025/06/13/recursion-biotech-job-layoffs-workforce-stocks-developing-medicine/
